nivolumab,ipilimumab
ono Pharmaceuticals,BMS,natera
['colorectal', 'breast', 'rectal', 'natera']
natera presents new colorectal and breast cancer data at esmo 2022, highlighting signatera's ability to inform treatment decisions in the adjuvant and neoadjuvant settings 
Health Tips and professional medical news